Oncology

The widespread overuse of adrenal CT scans, revealing that more than half of these imaging studies are performed unnecessarily, has been investigated in a new study.

A new post hoc analysis of the ADAURA trial highlights the role of osimertinib in detecting molecular residual disease (MRD) in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer (NSCLC).

Patients recovering from lung cancer surgery may face prolonged hospital stays when wildfires strike, according to new research examining the effects of wildfire disasters on post-operative recovery.

A deep learning model offering a powerful tool for predicting how patients with advanced non-small cell lung cancer (NSCLC) will respond to immune checkpoint inhibitors (ICIs), potentially improving treatment personalization, has been newly developed.

A phase II trial evaluating the combination of pembrolizumab and bevacizumab in patients with untreated melanoma brain metastases (MBM) has demonstrated substantial clinical activity and promising survival outcomes.

In a pivotal development for the oncology community, a recent retrospective study has demonstrated that continuing immunotherapy beyond disease progression offers significant survival benefits for patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

A recent study reveals a modest increase in early palliative care (PC) billing among Medicare beneficiaries diagnosed with distant-stage cancers from 2010 to 2019.

In Southeastern Michigan, Black men face disproportionately higher mortality rates from prostate cancer, often presenting with more advanced disease stages.

A recent study has revealed that adult survivors of childhood cancer face a significantly elevated risk of developing melanoma, underscoring the necessity for vigilant long-term monitoring and tailored preventive strategies.

A recent cohort study has highlighted significant disparities in comorbidity profiles among patients undergoing low-dose computed tomography (LDCT) for lung cancer screening.

Integrative sleep medicine is revolutionizing cancer care, as highlighted at the 21st Annual Miami Cancer Meeting (MCM) in Tampa, Florida, this January.

Early-onset breast cancer incidence in the U.S. is rising, but new research suggests the increase is not uniform across all states. A recent study analyzing trends from 2001 to 2020 found that breast cancer rates in women under 40 have increased significantly in 21 states, with distinct regional differences.

A long-term study of assisted reproductive technology (ART) has found no increased risk of endometrial cancer, addressing concerns about the potential long-term effects of fertility treatments.

A new treatment combination has emerged for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplant (ASCT).

18F-FDG PET and PET/CT scans show strong diagnostic accuracy in detecting histological transformations (HT) in indolent lymphomas, including Richter’s transformation (RT) in chronic lymphocytic leukemia (CLL), according to a new meta-analysis.

A machine learning model, SCORPIO, has shown promise in predicting the success of immune checkpoint inhibitors (ICIs) for patients with cancer.

A recent prospective cohort study highlights the incidence and clinical course of abemaciclib-induced interstitial lung disease (ILD) in patients with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC) previously treated with chemotherapy.

A new study has found that diet may play a key role in survival for women diagnosed with early-stage ovarian cancer.

The power of explainable artificial intelligence (xAI) combined with multimodal real-world data (RWD) to improve cancer prognosis across multiple cancer types was explored in a new study.

A new treatment for limited-stage small cell lung cancer (LS-SCLC) has been recommended for approval in the European Union following positive results from a Phase III trial.

In the battle against lung cancer, a recent editorial examines the effectiveness of risk prediction models in determining screening eligibility.

Lung cancer remains one of the deadliest diseases worldwide, with changing risk factors influencing mortality rates.

A recent multicenter Phase II trial has demonstrated that combining chemoradiotherapy (CRT) with aggressive local consolidative therapy (LCT) can improve survival rates in patients with Stage IV non-small cell lung carcinoma (NSCLC) presenting with oligometastases.

A Phase II trial examining neoadjuvant therapy for difficult-to-resect cutaneous basal cell carcinoma (BCC) demonstrates promising outcomes.

Immune checkpoint inhibitors, widely used in cancer therapy, have revolutionized oncology but come with the risk of severe immune-related adverse events, including checkpoint myocarditis.

A groundbreaking study has revealed that white button mushrooms (WBM) may reduce immune suppression and enhance anti-cancer immune responses in patients with prostate cancer.

Colorectal cancer (CRC) screening guidelines may need to be more tailored, according to new research that identifies optimal stopping ages for screening based on sex, comorbidity status, and prior screening history.

The U.S. Food and Drug Administration (FDA) approved a novel combination therapy for adults with KRAS G12C-mutated metastatic colorectal cancer (mCRC).

A new study has unveiled a groundbreaking cancer treatment approach using engineered extracellular vesicles to target both tumor cells and immunosuppressive stromal cells in the tumor microenvironment (TME).

A recent observational study has shown that AI can significantly enhance breast cancer detection rates in mammography screening without increasing unnecessary recalls.

Post-transplant care has demonstrated that collaboration between hematopoietic cell transplantation (HCT) specialists and local oncologists can safely enhance patient outcomes while reducing caregiver burdens in a recently published research article.

A Phase III clinical trial, ECHELON-3, has demonstrated survival benefits for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) using a combination therapy of brentuximab vedotin (BV), lenalidomide (Len), and rituximab (R).

Significant advancements in tailoring salvage therapy for pediatric patients with relapsed or refractory classic Hodgkin lymphoma (cHL) have been revealed in a recent clinical trial.

A recent study has unveiled a mechanism by which estrogen receptor-positive (ER+) breast cancer cells become more aggressive after spreading to the bone marrow.

A recent Phase I clinical trial has provided promising results for a novel immunotherapy approach to treat early-stage ERBB2-positive breast cancer.

A recent study suggests multi-ancestry polygenic risk scores (PRS) may help refine active surveillance strategies for low- to intermediate-risk prostate cancer.

Selpercatinib, a targeted RET kinase inhibitor, has demonstrated continued efficacy in treating RET fusion-positive non–small cell lung cancer (NSCLC) even after disease progression.

A recent Phase II clinical trial has revealed promising results for men with low-grade prostate cancer on active surveillance (AS).

A new AI-powered model predicts outcomes for breast cancer patients on CDK4/6 inhibitors, offering precise insights into treatment response and enabling personalized care.

In this study, patients with a recurrence scores greater than 31 exhibited significant improvements in survival outcomes when treated with taxane and anthracycline-based chemotherapy.

Findings, presented at SABCS 2024, support tamoxifen as an effective adjuvant therapy for reducing recurrence in women with “good-risk” DCIS who opt to skip RT.

Avoiding chest wall irradiation post-mastectomy is safe for most intermediate-risk breast cancer patients, improving quality of care.

A novel deep learning-based radiomic biomarker could significantly enhance prediction of response to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).

Patients with low-risk ductal carcinoma in situ (DCIS) who chose active monitoring over immediate surgery reported similar quality-of-life outcomes, according to findings from the COMET trial presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Risk-reducing surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved survival outcomes in BRCA-mutation carriers diagnosed with breast cancer at or before age 40, according to a study presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Active monitoring may be a safe and effective treatment option for patients with low-risk ductal carcinoma in situ (DCIS), according to the findings of the COMET trial presented at the San Antonio Breast Cancer Symposium (SABCS) 2024.

At the 2024 San Antonio Breast Cancer Symposium (SABCS), new Phase III trial data presented the promising results of imlunestrant, an oral next-generation selective estrogen receptor degrader (SERD), in patients with advanced breast cancer.

Daily glucocorticoid hormones, commonly prescribed to reduce inflammation, can significantly influence the progression of glioblastoma (GBM), the most aggressive brain cancer in adults, according to new research.

Patients with high-risk, BRCA-positive breast cancer receiving the PARP inhibitor olaparib after standard treatment continue to experience significant survival benefits, according to 6-year follow-up results from the Phase III OlympiA trial.

Socioeconomic barriers and medical distrust hindered COVID-19 vaccine completion among cancer survivors, a high-risk group for severe outcomes from the virus, according to a recent study.

Over the past 45 years, cancer prevention and screening interventions have averted nearly 6 million deaths from major cancers in the United States, according to new research.

Emerging data highlights a critical complication for patients with metastatic lung cancer undergoing treatment with immune checkpoint inhibitors (ICIs), including PD-1 and PD-L1 blockers.

Patients with cancer vaccinated against COVID-19 within 6 months before infection showed significantly higher survival rates, according to a new analysis from the ASCO COVID-19 Registry.

Agricultural pest management methods were explored in a new study to determine how they can be adapted to combat cancer treatment resistance.

Glucose restriction in the tumor microenvironment helps cancer cells survive chemotherapy by altering key metabolic pathways, reveals a new study.

A recent analysis of the IDEAL clinical trial highlights a breakthrough for early-stage breast cancer.

Patients with multiple sclerosis (MS) may experience a slightly increased risk of developing cancer compared to the general population, according to a new nationwide French study spanning 10 years.

Mailed fecal immunochemical testing (FIT) kits using centralized outreach significantly increases colorectal cancer (CRC) screening rates in underserved communities, according to the results of a new study.

The response to tamoxifen, a cornerstone drug in preventing breast cancer recurrence, may hinge on an unexpected factor: gut bacteria.

Even healthy breast tissue harbors rare populations of mutated epithelial cells, raising important questions about their role in breast cancer development.

A randomized clinical trial has revealed that pharmacological ascorbate (high-dose intravenous vitamin C) improves survival outcomes for patients with metastatic pancreatic cancer, a disease with notoriously low 5-year survival rates.

CAR T-cell therapy, a major advancement in treating hematologic cancers, has struggled to show consistent success in solid tumors.

A new Phase III clinical trial has revealed that combining nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) improves progression-free survival in patients with Stage III or IV classic Hodgkin’s lymphoma compared to the standard brentuximab vedotin with AVD (BV+AVD).

A recent study has spotlighted the regulatory divide between the US Food and Drug Administration’s (FDA) Accelerated Approval (AA) pathway and the European Medicines Agency’s (EMA) Conditional Marketing Authorization (CMA) process, showing stark differences in their cancer drug approvals.

Overtreatment of prostate cancer persists among men with limited life expectancy within the Veterans Affairs (VA) health system.

A genetic variant, the BIM deletion polymorphism (BDP), has been identified by researchers to significantly enhance leukemia stem and progenitor cells’ survival, making them resistant to common targeted therapies.

A powerful link between health insurance status and racial and ethnic disparities in advanced cancer diagnoses has been identified in a recently published study.

Prognostic value of specific visceral protein ratios in patients with colon cancer can offer healthcare professionals a novel approach to estimating progression-free survival (PFS) and overall survival (OS) in affected patients.

A recent study sheds light on how estrogen signaling affects immune response in breast cancer, potentially opening pathways for combined anti-estrogen and immunotherapy approaches.

Nearly half of patients with metastatic melanoma treated with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab have survived cancer-free, underscoring the impact of immunotherapy in advanced melanoma.

Duloxetine, a widely used and popular antidepressant, has been recalled by U.S. Food and Drug Administration (FDA) due to the detection of N-nitroso-duloxetine, a chemical suspected of being carcinogenic.

Diet quality could play a role in the progression of prostate cancer for men undergoing active surveillance.

The U.S. FDA has approved a wearable device for treating metastatic non-small cell lung cancer in adults. Used with PD-1/PD-L1 inhibitors or docetaxel, it showed a median survival of 13.2 months.

A new study from The University of Texas MD Anderson Cancer Center has revealed that a combination of dual immunotherapy and chemotherapy improves outcomes for patients with metastatic NSCLC who harbor specific mutations.

Breast cancer deaths have declined by 44% since 1989, but rising diagnoses and racial disparities highlight the need for targeted care and early detection.

Greater BRCA genetic testing among men has been highlighted as a critical need in a recently published review

One-third of popular social media articles about breast, colorectal, lung, and prostate cancer contained misleading or harmful information, according to a new study.

Inherited BRCA mutations may sharply increase the risk of early-onset multiple myeloma, according to new research.

Protective cells can be converted into tumor promoters after the immune system has been hijacked by cancer.

The effects of radiotherapy on patients with systemic sclerosis (SSc) who develop cancer is a subject of growing concern due to the potential exacerbation of SSc symptoms and the risks of radiotherapy-related toxicity.

A recent study by Stanford University School of Medicine, California, has uncovered a significant correlation between patients with cancer who do not opt for surgery and an elevated risk of suicide.

A recent study examining cancer incidence trends among adults born between 1920 and 1990, revealed a concerning increase in cancer rates among younger generations.

In a new study researchers have highlighted the benefit of using ultrasound to image women with high-risk of advanced invasive breast cancer.

Read the latest developments in treating synovial sarcoma, as the FDA grants accelerated approval to afamitresgene autoleucel for treatment

Research from the University of Miami Miller School of Medicine: a 10-gene biomarker that predicts the benefit of adjuvant chemotherapy for stage II and III colon cancer patients.

Best of ASCO 2024 Miami: FLOT improves survival in esophageal cancer, ctDNA guides colorectal therapy, and biomarkers show promising results.

A news article on how breast cancer can cause depression and anxiety in breast cancer survivors, and ways to treat this